Zhejiang Hisoar Stock Soars 9.96%, Hits Intraday High of CNY 6.07

Zhejiang Hisoar Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 9.96% on June 1, 2026. The stock reached an intraday high of CNY 6.07, marking a notable moment in its trading activity. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 0.27% on the same day. Over the past week, Zhejiang Hisoar has shown resilience with an 8.39% increase, while the one-month performance reflects a decline of 4.26%. Despite the recent gains, the company has faced challenges in the longer term, with a five-year annual growth rate in net sales of -5.79% and a concerning operating profit decline of 179.56%. The company's market capitalization is currently CNY 9,025 million, categorizing it as a mid-cap entity within the pharmaceuticals and biotechnology sector. Financial metrics indicate a low return on capital employed of 2.16%, highlighting issues with profitability. As the stock continues to navigate its market position, today's performance may reflect underlying trends in investor sentiment and market dynamics.